Fibrates for secondary prevention of cardiovascular disease and stroke

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Wang, Deren ^a   Liu, Bian ^a   Tao, Wendan ^a   Hao, Zilong ^a   Liu, Ming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; CLOFIBRATE; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT;

AGE; ALL CAUSE MORTALITY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LOW RISK POPULATION; META ANALYSIS; MYOPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; ADULT; AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; BEZAFIBRATE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL, HDL; CLOFIBRATE; CORONARY DISEASE; FEMALE; FENOFIBRATE; FIBRIC ACIDS; GEMFIBROZIL; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; STROKE;

EID: 84958635699     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009580.pub2     Document Type: Review

References (72)

1. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine 2010;362(17):1563-74.
2. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis 1972;15:177-83.
3. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. The Lancet 1996;347(9005):849-53.
4. Nilsson J, Ericsson CG, Hamsten A, Grip L, Svane B, De Faire U. BECAIT Bezafibrate following acute myocardial infarction: Important findings from the Bezafibrate Coronary Atherosclerosis Intervention Trial. Fibrinolysis and Proteolysis 1997;11(Suppl 1):159-62.
5. de Faire U, Ericsson CG, Grip L, Nilsson J, Svane B, Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). European Heart Journal 1996;17 Suppl F:37-42.
6. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). The American Journal of Cardiology 1993; Vol. 71, issue 11:909-15.
7. Goldenberg I, Benderly M, Goldbourt U, BIP Study Group. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. Journal of the American College of Cardiology 2008;51(4):459-65.
8. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Archives of Internal Medicine 2005;165(10):1154-60.
9. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; Vol. 102, issue 1:21-7.
10. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; Vol. 231:360-81.
11. Derosa G, Cicero AEG, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical Therapeutics 2004; Vol. 26:1599-607.
12. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Mänttäri M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Annals of Medicine 1993;25:41-5.
13. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; Vol. 325, issue 7373:1139.
14. Meade TW for the British Medical Research Council General Practice Research Framework and participating vascular clinics. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease. Current Controlled Trials Cardiovascular Medicine 2001;2:195-204.
15. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96(7):2137-43.
16. Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. British Medical Journal 1971;4:767-75.
17. Oliver MF. Ischemic heart disease: a secondary prevention trial using clofibrate (Atromid-S). Advances in Experimental Medicine & Biology 1972;26:255-9.
18. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. British Medical Journal 1971; Vol. 4, issue 5740:775-84.
19. Hirsch SB, Wechsler AF, Tourtellotte WW. Clofibrate for the treatment of occlusive cerebrovascular disease. The New England Journal of Medicine 1972;287(13):671.
20. The Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Stroke 1973; Vol. 4:684-93.
21. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; Vol. 285, issue 12:1585-91.
22. Rubin HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103(23):2828-33.
23. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. The New England Journal of Medicine 1999;341(6):410-8.
24. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC, Veterans' Affairs High-Density Lipoprotein Intervention Trial, Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney International 2004;66(3):1123-30.
25. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet 2001;357(9260):905-10.
26. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005;366(9500):1849-61.
27. Tonkin A, Hunt D, Voysey M, Kesaniemi A, Hamer A, Waites J, et al. Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. American Heart Journal 2012;163(3):508-14.
28. Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, et al. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arteriosclerosis, Thrombosis & Vascular Biology 2014;34:1298-306.
29. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, et al. Diabetes intervention study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14(4):308-17.
30. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. The New England Journal of Medicine 1987;317(20):1237-45.
31. Li XP, Gong HR, Huang XS, Huang WY, Zhao SP. The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome. Lipids in Health & Disease 2013;12:133.
32. Rottiers R, van Egmond J. A one year double blind study of the effect of halofenate and clofibrate in patients with hyperlipoproteinemia. Acta Clinica Belgica 1975;30(5):398-408.
33. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998;21(4):641-8.
34. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC, Veterans' Affairs High-Density Lipoprotein Intervention Trial, Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney International 2004;66(3):1123-30.
35. Chong Kun Dang Pharmaceutical. Efficacy and safety of fenofibrate added on to atorvastatin compared with atorvastatin in mixed hypercholesterolemic patient (CKD-337). http://clinicaltrials.gov/show/NCT01956201 2013.
36. Oh HK. Efficacy and safety of fenofibrate added on to atorvastatin compared with atorvastatin. http://clinicaltrials.gov/show/NCT019562011 2013.
37. Koval O. Simvastatin and fenofibrate vs simvastatin alone in patients with type 2 diabetes mellitus and acute coronary syndrome. https://clinicaltrials.gov/show/NCT02015988 2013.
38. Karen L, Furie SE, Kasner RJ, Adams GW, Albers RL, Bush SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42(1):227-76.
39. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102(1):21-7.
40. Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. American Journal of Cardiology 2007;99(6A):19C-21C.
41. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arteriosclerosis and Thrombosis: a Journal of Vascular Biology/American Heart Association 1993;13(5):702-11. [PUBMED: 8485122]
42. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256(20):2835-8.
43. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Annals of Epidemiology 1992;2(1-2):23-8.
44. de Graaf J, Hendriks JC, Demacker PN, Stalenhoef AF. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arteriosclerosis and Thrombosis: a Journal of Vascular Biology/American Heart Association 1993;13(5):712-9. [PUBMED: 8485123]
45. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 2011;32(11):1345-61.
46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
47. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. The Lancet 1996;347(9005):849-53.
48. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Current Atherosclerosis Reports 2004;6(2):148-57.
49. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet 2005;366(9500):1849-61.
50. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. American Journal of Medicine 1977;62(5):707-14.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk 1996;3(2):213-9. [PUBMED: 8836866]
53. Expert Dyslipidemia Panel of the International Atherosclerosis Society. An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia -full report. Journal of Clinical Lipidology 2014;8(1):29-60.
54. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 2010;375:1875-84.
55. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117411 patients. BMJ 2014;349:g4379.
56. Khoury N, Goldberg AC. The use of fibric acid derivatives in cardiovascular prevention. Current Treatment Options in Cardiovascular Medicine 2011;13:335-42.
57. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. The Lancet 1977;1(8019):965-8.
59. Rabar S, Harker M, O'Flynn N, Wierzbicki AS, Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ 2014;349:g4356.
60. Nissen SE. Atherosclerosis in 2010: New therapeutic insights. Nature Reviews. Cardiology 2011;8:70-2.
61. Nordmann AJ, Ferreira-González I, Kasenda B, Saccilotto R, Bassler D, Bhatnagar N, et al. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD009753]
62. Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Current Opinion in Lipidology 1999;10(2):151-9.
63. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011;123(4):e18-209.
64. Scott R, O'Brien R, Fulcher G, Pardy C, d'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009;32(3):493-8.
65. Staels B, van Tol A, Andreu T, Auwerx J. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arteriosclerosis and Thrombosis 1992;12(3):286-94.
66. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-93.
67. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. The New England Journal of Medicine 1991;325(6):373-81.
68. Tikkanen MJ, Laakso M, Ilmonen M, Helve E, Kaarsalo E, Kilkki E, et al. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diabetes Care 1998;21(4):477-81. [PUBMED: 9571327]
69. Bloomfield RH, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001;103:2828-33.
70. World Health Organization. Cardiovascular disease. http://www.who.int/cardiovascular_diseases/priorities/en/ (accessed 16 March 2011).
71. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: World Health Organization; 2014.
72. World Health Organization. Cardiovascular diseases (CVDs) [Updated January 2015]. http://www.who.int/mediacentre/factsheets/fs317/en/ 2015.